All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche, and Syndax, and supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
The QUIWI trial: What is the potential of quizartinib in patients with wild-type FLT3?
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Adrian Mosquera Orgueira, Santiago Clinic Hospital CHUS, Santiago, ES. We asked, The QUIWI trial: What is the potential of quizartinib in patients with wild-type FLT3?
The QUIWI trial: What is the potential of quizartinib in patients with wild-type FLT3?
Mosquera Orguiera provides an overview of the phase II QUIWI trial (NCT04107727) investigating the addition of quizartinib, an FLT3 inhibitor, to standard chemotherapy vs placebo in patients aged 18–70 years with newly diagnosed FLT3-internal tandem duplication wild-type acute myeloid leukemia. He then highlights the initial results, which suggest that quizartinib is associated with a survival benefit vs placebo in this patient population. Mosquera Orguiera concludes by discussing a biological correlative analysis, indicating that gene expression signatures linked with an FLT3-internal tandem duplication may predict response to quizartinib.
Your opinion matters
10 votes - 23 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox